3-(2-nitro-1-phenylethyl)-1-phenyl-1H-indole | 1446648-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-(2-nitro-1-phenylethyl)-1-phenyl-1H-indole
• 英文别名: 3-(2-nitro-1-phenylethyl)-1-phenylindole
• CAS: 1446648-39-0
• 化学式: C₂₂H₁₈N₂O₂
• 分子量: 342.397
• InChiKey: LGCHLDAWVWNNFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.04
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  48.07
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  碘苯 、 3-(2-硝基-1-苯乙基)-1H-吲哚 在 potassium phosphate 作用下， 以 二甲基亚砜 为溶剂， 反应 1.5h， 以25.3%的产率得到3-(2-nitro-1-phenylethyl)-1-phenyl-1H-indole
  参考文献：
  名称：

  Allosteric modulators of CB1 cannabinoid receptors

  摘要：

  本发明涉及新颖的杂环衍生物，它们是大麻素受体1（CB1）的别构调节剂，可用于治疗或预防与内大麻素功能障碍和涉及大麻素受体CB1亚型的神经和精神障碍相关的疾病；涉及它们的制备方法；包括它们的药物组合物；以及使用它们的方法。

  公开号：

  US09556118B2

文献信息

• [EN] CANNABINOID TYPE 1 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR CANNABINOÏDE DE TYPE 1
  申请人：UNIV TORONTO

  公开号：WO2016029310A1

  公开（公告）日：2016-03-03

  The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

  本公开涉及公式（I）的吲哚衍生物，这些衍生物是大麻素类型1受体调节剂，对于治疗需要调节受体的疾病是有益的；涉及它们的制备方法；包含它们的药物组合物；以及使用它们的方法。
• [EN] ALLOSTERIC MODULATORS OF CB1 CANNABINOID RECEPTORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS DE CANNABINOÏDES CB1
  申请人：UNIV NORTHEASTERN

  公开号：WO2013103967A1

  公开（公告）日：2013-07-11

  The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

  本发明涉及新的杂环衍生物，它们是大麻素受体1（CB1）的别构调节剂，可用于治疗或预防与内源性大麻素功能障碍有关的神经和精神障碍以及涉及大麻素受体CB1亚型的疾病；涉及它们的制备方法；涉及包含它们的制药组合物；以及使用它们的方法。
• ALLOSTERIC MODULATORS OF CB1 CANNABINOID RECEPTORS
  申请人：Northeastern University

  公开号：US20150005346A1

  公开（公告）日：2015-01-01

  The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

  本发明涉及新型杂环衍生物，它们是大麻素受体1（CB1）的别构调节剂，并且适用于治疗或预防与内源性大麻素功能障碍和涉及CB1亚型的大麻素受体相关的神经和精神障碍以及疾病；涉及它们的制备方法；涉及包含它们的制药组合物；以及使用它们的方法。
• Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure–Activity Relationship Studies
  作者：Dow P. Hurst、Sumanta Garai、Pushkar M. Kulkarni、Peter C. Schaffer、Patricia H. Reggio、Ganesh A. Thakur

  DOI：10.1021/acsmedchemlett.9b00256

  日期：2019.8.8

  Positive allosteric modulation of the cannabinoid 1 receptor (CB1R) has demonstrated distinct therapeutic advantages that address several limitations associated with orthosteric agonism and has opened a promising therapeutic avenue for further drug development. To advance the development of CB1R positive allosteric modulators, it is important to understand the molecular architecture of CB1R allosteric site(s). The goal of this work was to use Force-Biased MMC Simulated Annealing to identify binding sites for GAT228 (R), a partial allosteric agonist, and GAT229 (S), a positive allosteric modulator (PAM) at the CB1R. Our studies suggest that GAT228 binds in an intracellular (IC) TMH1-2-4 exosite that would allow this compound to act as a CB1 allosteric agonist as well as a CB1 PAM. In contrast, GAT229 binds at the extracellular (EC) ends of TMH2/3, just beneath the EC1 loop. At this site, this compound can act as CB1 PAM only. Finally, these results were successfully validated through the synthesis and biochemical evaluation of a focused library of compounds.
• Allosteric Modulators of CB1 Cannabinoid Receptors
  申请人：Northeastern University

  公开号：US20170197918A1

  公开（公告）日：2017-07-13

  The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.